title: P&T Committee review of fluconazole: an effective alternative to antifungal therapy.
abstract: Fluconazole is a new antifungal agent available in both oral and parenteral formulations. According to the experts in this roundtable discussion, fluconazole represents a major clinical advance in the treatment of candidiasis and cryptococcosis in cancer patients, patients with AIDS, organ transplant recipients, and other patients at risk for opportunistic mycoses. The pharmacokinetic profile for fluconazole permits infrequent dosing and also makes it ideal for tissue site infections. Fluconazole's low toxicity gives it an advantage over currently available antifungal therapy and will permit prompt presumptive treatment of selected infections.
authors: College of Physicians and Surgeons of Columbia University, New York City.
authors: H C
authors: HC
authors: Neu
authors: J E
authors: JE
authors: Bennett
authors: G P
authors: GP
authors: Bodey
authors: R H
authors: RH
authors: Rubin
authors: J J
authors: JJ
authors: Schentag
authors: A M
authors: AM
authors: Sugar
mesh_terms: D000935:Antifungal Agents; D015725:Fluconazole / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005572:Formularies, Hospital as Topic; D006801:Humans; D010606:Pharmacy and Therapeutics Committee; D014481:United States
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole